by Jason Parker — June 22, 2022 DURHAM – Phononic is adding to its leadership team and has appointed Larry Yang, a former executive at Fitbit and Google as well as a former employee at Sun Microsystems, Microsoft, and Cisco, to the role of chief product officer. In that role, Yang will lead product marketing, management, and design engineering […]
Rex Health Ventures enables groundbreaking work to advance the future of health
Rex Health Ventures (RHV) enables groundbreaking work by investing in and fostering companies and technologies that advance the future of health.
- Entrepreneur-friendly strategic investor that speeds access to new healthcare products and services to improve patient care
- Established by UNC REX Healthcare in 2012 as part of its commitment to innovation
- Partners with emerging companies throughout North Carolina and the U.S.
- Leverages the talent and subject matter experts across the UNC REX and UNC Health Care network
Portfolio Spotlight: Phononic
Phononic is revolutionizing cooling and heating with solid-state thermal management solutions. Named to CNBC’s 2016 Disruptor 50 list for its innovation within the cooling and heating industry, as well as CNBC’s Disruptor 50 list for both 2016 and 2017, Phononic provides solid-state semiconductor technology that can be applied to everything from refrigeration to fiber optics, removing the barriers of traditional approaches and ushering in a new era of cooling and heating.
UNC REX served as the first testing site for Phononic’s medical grade refrigerator, which will now be installed throughout the new NC Heart and Vascular hospital. Learn more in this video.
Meet the Rex Health Ventures Team
Get the latest investment news from Rex Health Ventures:
Report offers insight into over 50 million controlled substance medication transactions in more than 230 hospitals June 01, 2022 09:15 AM Eastern Daylight Time WASHINGTON–(BUSINESS WIRE)–Kit Check, the industry leader in Medication Intelligence™ solutions for hospitals, today announced the findings of its first-ever Diversion Trends Report, which analyzed controlled substance medication transactions in more than […]
SP-624 has a novel epigenetic mechanism to enhance neuroplasticity in brain regions involved in depression, namely the hippocampus and prefrontal cortex May 26, 2022 08:10 AM Eastern Daylight Time MORRISVILLE, N.C.–(BUSINESS WIRE)–Arrivo BioVentures announced today that the company has closed enrollment of a phase 2 clinical study with its most advanced program, SP-624, after having enrolled […]